Canadian Longitudinal Study on Aging, Canada

Certification Status: Invite Member

Registration Status: Completed

Objective: The Canadian Longitudinal Study (CLSA) is a research platform to enable state-of-the-art, interdisciplinary population-based research and evidenced-based decision-making that will lead to better health and quality of life for Canadians. The study has enrolled 50,000 participants aged 45-85 at baseline across the country. Blood and urine are collected on 30,000 participants every three years beginning in 2012. The CLSA is a strategic initiative of the Canadian Institutes of Health Research (CIHR). Support for the CLSA has been provided by the Government of Canada through the CIHR and the Canada Foundation for Innovation.

Registered Biobank Name	Canadian Longitudinal Study on Aging
Biobank Leader	Dr. Cynthia Balion
Country	Canada
Email for biobank inquiries	balion@hhsc.ca
Principal Investigator	Dr. Parminder Raina, Dr. Christina Wolfson, Dr. Susan Kirkland
Website	https://www.clsa-elcv.ca/
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).